Literature DB >> 6086852

Cyclic nucleotides in experimental and human brain tumors.

G Racagni, S Pezzotta, M T Giordana, E Iuliano, I Mocchetti, G Spanu, G Sangiovanni, P Paoletti.   

Abstract

It is well known that the system of cyclic nucleotides plays an important role in cell differentiation and proliferation. Cyclic AMP is capable of stimulating cell growth, and cyclic GMP is thought to control cell division and growth. The authors measured adenylcyclase activity (AC) and cGMP content in the tumor latency period and in early neoplastic proliferations in rats with brain tumors induced by transplacental ethylnitrosourea (ENU). AC activity, which is high during the first days of life, decreases until it reaches, at the 60th day, levels lower than those in control animals. Cyclic GMP, on the contrary, increases during the first month in treated animals and remains consistently higher than controls up to the 45th day. In fully developed experimental brain tumors (mixed gliomas, isomorphic and polymorphic oligodendrogliomas) the percentage of reduction in AC activity is significantly higher. AC activity was measured also in human tumoral tissue. In malignant tumors it is markedly lower than in benign tumors. In the same patients cAMP in the cerebrospinal fluid was measured with results similar to those obtained in tissues. These findings confirm that the system of cyclic nucleotides is implicated in all the developmental phases of brain tumors and therefore may reveal how research can clarify the first transformations of tumoral cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6086852     DOI: 10.1007/bf00153643

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

Review 1.  Biologic regulation through opposing influences of cyclic GMP and cyclic AMP: the Yin Yang hypothesis.

Authors:  N D Goldberg; M K Haddox; S E Nicol; D B Glass; C H Sanford; F A Kuehl; R Estensen
Journal:  Adv Cyclic Nucleotide Res       Date:  1975

2.  Difference in the cyclic adenosine 3',5'-monophosphate levels in normal and transformed cells.

Authors:  J R Sheppard
Journal:  Nat New Biol       Date:  1972-03-01

3.  Adenyl cyclase, phosphodiesterase and cyclic AMP dependent protein kinase of malignant glial cells in culture.

Authors:  J P Perkins; E H Macintyre; W D Riley; R B Clark
Journal:  Life Sci I       Date:  1971-09-15

4.  The response of human cerebrum adenyl cyclase to biogenic amines.

Authors:  H Shimizu; S Tanaka; T Suzuki; Y Matsukado
Journal:  J Neurochem       Date:  1971-06       Impact factor: 5.372

5.  Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

Authors:  J W Kebabian; G L Petzold; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1972-08       Impact factor: 11.205

6.  Regulation of the cyclic guanosine 3'-5' monophosphate system in human brain tumors.

Authors:  L Frattola; A Carenzi; C Cerri; K Kumakura; M Trabucchi
Journal:  Acta Neurol Scand       Date:  1976-11       Impact factor: 3.209

7.  Stimulation of adenosine 3':5'-monophosphate formation by prostaglandins in human astrocytoma cells. Inhibition by nonsteroidal anti-inflammatory agents.

Authors:  R Ortmann; J P Perkins
Journal:  J Biol Chem       Date:  1977-09-10       Impact factor: 5.157

8.  Cyclic AMP and adenyl cyclase in brain tumors.

Authors:  M A Furman; K Shulman
Journal:  J Neurosurg       Date:  1977-04       Impact factor: 5.115

9.  Immunological, biochemical, ultrastructural, and electrophysiological characteristics of a human glioblastoma-derived cell culture line.

Authors:  P M Black; P L Kornblith; P F Davison; T M Liszczak; L P Merk; B H Smith; P E McKeever; E A Quindlen
Journal:  J Neurosurg       Date:  1982-01       Impact factor: 5.115

10.  Cerebral tumours induced by ENU; changes of adenylate cyclase activity in the tumour latency time.

Authors:  G Racagni; M T Giordana; S Pezzotta; F Bruno; P Paoletti; D Schiffer
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

View more
  6 in total

1.  {Beta}2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells.

Authors:  L Toll; L Jimenez; N Waleh; K Jozwiak; A Y-H Woo; R-P Xiao; M Bernier; I W Wainer
Journal:  J Pharmacol Exp Ther       Date:  2010-11-11       Impact factor: 4.030

2.  Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.

Authors:  Patricia Goldhoff; Nicole M Warrington; David D Limbrick; Andrew Hope; B Mark Woerner; Erin Jackson; Arie Perry; David Piwnica-Worms; Joshua B Rubin
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

3.  An experimental trial of cyclic nucleotides on multicellular spheroids derived from human brain tumours.

Authors:  N Oktar; J L Darling; D G Thomas
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

4.  Local interstitial chemotherapy with sustained release bucladesine in de novo glioblastoma multiforme: a preliminary study.

Authors:  Tayfun Dalbasti; Nezih Oktar; Sedat Cagli; Nurcan Ozdamar
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

5.  Treating brain tumors with PDE4 inhibitors.

Authors:  Rajarshi Sengupta; Tao Sun; Nicole M Warrington; Joshua B Rubin
Journal:  Trends Pharmacol Sci       Date:  2011-03-28       Impact factor: 14.819

Review 6.  An integrative view on sex differences in brain tumors.

Authors:  Tao Sun; Anya Plutynski; Stacey Ward; Joshua B Rubin
Journal:  Cell Mol Life Sci       Date:  2015-05-19       Impact factor: 9.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.